US OptionsDetailed Quotes
ALXO240719C14000
- 0.80
- 0.000.00%
15min DelayTrading Jun 4 09:30 ET
0.00High0.00Low
0.00Open0.80Pre Close0 Volume10 Open Interest14.00Strike Price0.00Turnover2272.53%IV134.55%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type0.3271Delta0.0642Gamma7.89Leverage Ratio-1.8135Theta0.0000Rho2.58Eff Leverage0.0009Vega
ALX Oncology Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
13
3
$ALX Oncology(ALXO.US$ ALX Oncology Reports Clinical Data From Ongoing Phase 1/2 Investigator-Sponsored Trial Of Evorpacept In Combination With R2 In Patients With Indolent And Aggressive R/R B-NHL
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
Benzinga· 5 mins ago
The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combination with standard R2 treatment. The regimen was well to...
1
$ALX Oncology(ALXO.US$ $ALXO 7,370,690 Shares of Common StockPre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 7,370,690 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to certain investors, pre-funded warrants to
$Avalo Therapeutics(AVTX.US$
Poor Performance So Far
Over the past few weeks, we have seen a lot of unusual activity in this ticker symbol. If there is anyone out there who knows why activity has picked up in AVTX, then please enlighten me.
Over the past few years, putting money into this company has been losing bet. Any stock that is in a long-term downtrend is usually something that I would stay away from.
Intriguing Technical Developmemts
Over the past few weeks,...
Poor Performance So Far
Over the past few weeks, we have seen a lot of unusual activity in this ticker symbol. If there is anyone out there who knows why activity has picked up in AVTX, then please enlighten me.
Over the past few years, putting money into this company has been losing bet. Any stock that is in a long-term downtrend is usually something that I would stay away from.
Intriguing Technical Developmemts
Over the past few weeks,...
+4
9
3
$ALX Oncology(ALXO.US$ 7.37M shares + 1.25M pre-funded warrants at $6.38
1
3
$ALX Oncology(ALXO.US$ should we jump off the boat
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long